infection control and hospital epidemiology january 2013, vol. 34, no. 1 o r i g i n a l a r t i c l e objectives. To analyze infectious complications that occur in patients who receive extracorporeal membrane oxygenation (ECMO), associated risk factors, and consequences on patient outcome.
Infections Acquired by Adults
design. Retrospective observational survey from 2005 through 2011.
participants and setting. Patients who required ECMO in an Australian referral center.
methods. Cases of bloodstream infection (BSI), catheter-associated urinary tract infection (CAUTI)
, and ventilator-associated pneumonia (VAP) that occurred in patients who received ECMO were analyzed.
results. A total of 146 ECMO procedures were performed for more than 48 hours in 139 patients, and 36 patients had a total of 46 infections (30.1 infectious episodes per 1,000 days of ECMO). They included 24 cases of BSI, 6 of them secondary to VAP; 23 cases of VAP; and 5 cases of CAUTI. The most frequent pathogens were Enterobacteriaceae (found in 16 of 46 cases), and Candida was the most common cause of BSI (in 9 of 24 cases). The Sequential Organ Failure Assessment score before ECMO initiation and the number of days of support were independently associated with a risk of BSI, with odds ratios of 1. conclusion. The probability of infection increased with the duration of support and the severity of illness before initiation of ECMO. Infections affected length of stay but did not have an impact on mortality. The use of extracorporeal membrane oxygenation (ECMO) in adults for severe cardiac or reversible pulmonary failure has become more common in selected intensive care units (ICUs) over the past few decades. [1] [2] [3] [4] [5] The reported mortality among patients who undergo ECMO remains high, with death reflecting both the severity of the underlying illness and adverse events relating to ECMO. 2, 4, [6] [7] [8] In terms of the frequency of complications during ECMO, infectious complications rank second after hemorrhagic complications and have been reported in up to 45% of patients. 9 Patients who receive ECMO are at a high risk of healthcare-associated infection, especially bloodstream infection (BSI), because of the multiple potential portals of entry, which include standard invasive catheters, frequent need for dialysis, ECMO cannualae, and, in cases of central venoarterial (VA) ECMO, an open chest wound. [9] [10] [11] Furthermore, although invasive lines can be removed or changed, it is not feasible to do this with ECMO. Infectious complications have been largely studied in pediatric [10] [11] [12] [13] populations, but adult series are less commonly reported. 9, 14, 15 A detailed examination of the microbiology and risk factors for infective complications during ECMO may assist in selection of empirical treatment regimens and development of preventive measures. Furthermore, the impact of infection on mortality remains controversial, with some authors reporting a poorer prognosis in patients who experienced an infectious episode during ECMO 12,16 and others not finding an association.
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infectious complications in adults who received ECMO during a 5-year period. It describes the risk factors for infection and their association with mortality and length of stay (LOS).
methods

Setting
Alfred Hospital is a quaternary university-attached referral hospital that provides heart and lung transplantation services for Victoria, South Australia, and Tasmania; is 1 of 2 adult trauma centers within Victoria; and is the state burns center. The ICU is one of the largest Australian ICUs, with a capacity of 45 beds and more than 2,000 admissions per year. The ECMO service, in conjunction with a state-based ambulance retrieval service, performs ECMO retrievals from the Australian states of Victoria, Tasmania, and South Australia. Patients retrieved had ECMO initiated in the referral hospital by a retrieval team from Alfred Hospital with use of percutaneous cannulation. They were then transferred while receiving ECMO to the Alfred Hospital ICU.
Patients and Data
Patients over the age of 16 years who received ECMO support for more than 48 hours during the period January 2005 through June 2011 were enrolled. Clinical data were obtained from a prospectively updated registry of ECMO patients and from a prospectively maintained ICU clinical database and were supplemented by a retrospective review of medical records. Demographic characteristics and comorbidities, hospital and ICU admission dates, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and main diagnosis at ICU admission were recorded. Immunosuppression was defined as immunosuppressive drug treatment (including systemic corticosteroids), AIDS, or hematological malignancy. The following parameters were collected before the initiation of ECMO: occurrence of a cardiac arrest, Sequential Organ Failure Assessment (SOFA) score, 17 plasma lactate level, ratio, and the days in ICU and duration of mePaO : FiO 2 2 chanical ventilation (MV) before ECMO. Data on duration of ECMO support, requirement for catecholamines, and renal replacement therapy during ECMO were also collected. This study was approved by the Alfred Hospital Health Human Research Ethics Committee.
ECMO Procedures
The decision to use ECMO to support a patient in this series was made by the managing intensive care specialist or the managing cardiac surgeon for intraoperative cardiac support. ECMO for cardiac failure was initiated for acute, potentially reversible cardiac failure and for chronic or irreversible cardiac failure as a bridge to longer-term mechanical support or cardiac transplantation. In contrast, ECMO for respiratory failure was limited to acute reversible respiratory failure and was not used as bridging support for patients with chronic respiratory failure listed for lung transplantation in this cohort. The time period of this study was chosen because it represented a stable period with respect to equipment, staffing models, and clinical practice. Bedside care was delivered by trained ICU nursing staff at a ratio of . patient : nurse 1 : 1 Medical care was provided by a medical team under the supervision of intensive care specialists, all of whom were trained in ECMO. Perfusion services were not involved.
ECMO circuits were configured according to patient need and clinical context. For respiratory failure, VV ECMO was delivered through percutaneously placed femoro-femoral cannulae (Medtronic) with an additional jugular access cannula if required. Two-stage jugular cannulae (Avalon Elite) were used in only 2 patients. Percutaneous VA ECMO for cardiac support was provided using peripheral femorofemoral cannulae with an ante-grade 8.5 French distal perfusion cannula (Mayo) to prevent limb ischaemia. Central VA ECMO was initiated intraoperatively at the discretion of the managing cardiac surgeon. Continuous renal replacement (Prisma and then Prismaflex) was performed via the ECMO circuit.
ECMO patients with no active bleeding received anticoagulation therapy with heparin targeted to an activated partial thromboplastin time of 50-70 seconds. Surgical procedures, if performed, were done without heparin and with antifibrinolytic therapy and normalization of platelet and standard clotting indices.
Antibiotic Management and Microbiological Samples
Antibiotic prophylaxis for ECMO was not routine except in patients who underwent open-heart surgical procedures and those who received ventricular assist devices from ECMO. Empirical, standardized broad-spectrum antibiotic treatment was initiated according to ICU and anti-infective guidelines for suspected and confirmed sepsis when deemed indicated by the managing intensivist. Specimens for culture were obtained at the discretion of the treating clinician, and no systematic screening procedures were performed. Standardized prophylactic or selective decontamination antibiotic regimens were not used.
Definition of Nosocomial Infection
Nosocomial BSI, catheter-associated urinary tract infection (CAUTI), and hospital-acquired pneumonia were considered if they occurred more than 48 hours after ECMO initiation and within 72 hours after ECMO cessation. Wound infections were not measured prospectively and therefore were not included. Infectious complications were defined retrospectively using the Centers for Disease Control and Prevention (CDC) and National Healthcare Safety Network (NHSN) criteria with modifications as outlined below. 18 Hospital guidelines recommended obtaining blood samples for culture from pe-ripheral veins or central venous devices when peripheral veins were not easily accessible. Because all patients received MV, all cases of hospital-acquired pneumonia were considered to be ventilator-associated pneumonia (VAP) by definition. VAP was retrospectively diagnosed if all 3 of the following were present: (1) fever (temperature 138ЊC) with no other recognized cause or leukopenia (!4,000 white blood cells [WBCs]/mL) or leucocytosis (112,000 WBC/mL); (2) new onset of purulent sputum or change in the character of sputum with a positive nonquantitative culture result; and (3) 2 or more serial chest radiographs with findings that indicated new, progressive, or persistent infiltrate consolidation or cavitation. Sputum samples were obtained by either tracheal aspiration or bronchoalveolar lavage. A VAP episode was assessed as definite when the criteria were present and pneumonia was diagnosed and treated by the intensivist. Because of discrepancies in the interpretation of criteria, we considered a category of highly probable pneumonia, in which all criteria appeared to have been met but pneumonia was not diagnosed or treated by the intensivist or 2 of the 3 criteria were met but pneumonia was diagnosed and treated by the intensivist.
Outcomes
Mortality during hospitalization in the ICU and in the hospital were prospectively recorded, as was successful weaning from ECMO. Lengths of stay in the ICU and in the hospital after ECMO weaning were also recorded and analyzed.
Statistical Analysis
All analyses were performed using Stata, version 10.0 (Stata). When ECMO was initiated in another center, only the days at Alfred Hospital were taken into account for the number of red blood cells (RBCs) given per day of ECMO. In case of change of ECMO mode, the first type was considered for the study analysis. Categorical variables were compared between groups with a Fisher exact test, and continuous variables were compared with a Mann-Whitney U test for nonparametric data. Statistical regression models were constructed on the basis of factors found to be associated with outcomes (ie, mortality and infection) using backwards stepwise regression based on . In the mortality models, P ! .02 factors that were available at the time of starting ECMO were considered in a prognostic model, and the effect of complications (ie, bleeding and infection) was considered in a complications model. In instances in which variables were expected to be collinear (eg, SOFA score and APACHE II score), only 1 variable was included in the model. A 2-sided P value of .05 was considered to be statistically significant.
results
Patient Characteristics
From January 2005 through June 2011, 151 critically ill adult patients underwent 158 ECMO procedures in the ICU of Alfred Hospital. Twelve of these 158 ECMO procedures continued for less than 48 hours and were not included in the study. All of the patients received MV and had a urinary catheter and central lines in addition to the ECMO support. Patient characteristics and details of the ECMO procedures are summarized in Table 1 . The primary indications of the 96 VA ECMO episodes were (1) early (primary) heart graft dysfunction after heart transplantation ( );
Infections at All Sites
A total of 36 patients experienced 46 infectious episodes. There were 24 episodes of BSI, of which 18 were in patients without pneumonia and 6 were in patients with pneumonia. There were 23 episodes of VAP, of which 17 did not involve concomitant identified bacteremia; 6 episodes were assessed as definite VAP, and 17 episodes were assessed as highly probable VAP. There were 5 episodes of CAUTI. The rate of overall infection was 30.1 cases per 1,000 days of ECMO support.
Enterobacteriaceae were the causative microorganism in 16 infections and the most common isolate among patients with VAP ( ; 56%). The Enterobacteriaceae responsible for n p 13 VAP included Enterobacter cloacae (4 cases), Serratia species (3 cases), Klebsiella pneumonia (3 cases), Escherichia coli (3 cases), and Enterobacter aerogenes (1 case). Other gram-negative bacilli and methicillin-resistant Staphylococcus aureus (MRSA) were responsible for 6 (26%) and 5 (22%) of the VAP episodes, respectively. One episode was attributable to 2 pathogens. All of the CAUTIs were attributable to gramnegative bacilli (Enterobacteriaceae in 4 cases and Pseudomonas aeruginosa in 1 case). Of the 36 patients with ECMO procedures who experienced at least 1 infection episode, the duration of support and the total number of transfused RBC units were significantly associated with infection occurrence (Table 1 ). In the multivariate analysis, the duration of support was the only independent risk factor for infection, with an odds ratio (OR) of 1.06 (95% confidence interval [CI], 1.00-1.12;
). P p .043
BSI
The rate of BSI was 15.7 cases per 1,000 days of ECMO support, with 24 cases occurring during 21 ECMO episodes. The BSIs were related to VAP in 6 cases, to a surgical-site infection in 1 case, and to a central line in 1 case (based on a positive culture from a line tip). We were not able to define retrospectively the portal of entry in the other cases; on the basis of modified CDC and NHSN definitions, these BSIs would therefore be ECMO-associated BSIs or central line-associated BSIs. Only 1 BSI was secondary to 2 pathogens. Candida species, which were responsible for 9 cases, were the most frequent pathogen; the majority of cases were due to Candida albicans (6 cases). Other pathogens isolated included Enterococcus species in 5 cases, Enterobacteriaceae in 6 cases, other gram-negative bacilli in 1 case, and S. aureus in 2 cases. Coagulase-negative Staphylococcus was responsible for only 1 BSI. In the univariate analysis, the duration of ECMO, the SOFA score at ECMO initiation, and the total of RBC units transfused over the course of the ECMO procedure were significantly associated with BSI occurrence ( ). However, the proportion P p .029 of patients successfully weaned from ECMO and the hospital mortality rate were not different between infected and uninfected patients (Table 1) . Patients with a BSI had a longer ICU LOS after ECMO weaning (median LOS in the ICU, 17 days [IQR, 12-19 days]) than did uninfected patients (median length of stay in the ICU, 10 days [IQR, 3-19 days]; P p ; Table 2 ). .0241 discussion This study describes nosocomial infections associated with ECMO in critically ill adults. Over a period of more than 5 years, we showed that almost a quarter of patients experienced 1 or more infectious episodes. Whatever the type of infection, the duration of ECMO was an independent substantial risk factor. BSIs were also associated with patient illness severity at ECMO initiation. We also found a high prevalence of fungemia in patients who received ECMO, which probably reflects patient illness severity and the long-standing use of broad-spectrum antibiotics. Despite a longer LOS in the ICU and at the hospital, infected patients had a mortality rate similar to that among uninfected patients.
Incidence and Microbiological Features
At least 1 infection complicated a quarter of ECMO procedures. The reported rate of infection in the literature varies widely between 3.5% and 45%. [9] [10] [11] [12] [13] [14] [15] [16] 20, 21 This considerable heterogeneity may be secondary to differences in study methodology, because different types of infections were included and different definition criteria were used. For instance, some authors reported infections that occurred up to 7 days after ECMO discontinuation, whereas others considered the mere presence of yeast in urine to be evidence of urinary tract infection. 10 To facilitate the comparison, our study detailed the rate of infection expressed per 1,000 ECMO days; however, the rate of BSI depends on the classification of bacteremia associated with VAP. Our rate was higher than those previously and usually reported in adult cohorts that have included between 71 and 334 patients. 9, 14, 15 The largest cohort study to date, which involved 2,298 adults, recently reported rates similar to our findings (30.6 infectious episodes per 1,000 days of ECMO), although the definition of infection was not reported by the authors. 19 Our BSI rate was slightly lower than that reported by Burket in a cohort study involving 71 adults (15.7 cases per 1,000 ECMO days in our study, compared with 18.8 cases per 1,000 ECMO days). 9 Candida species were found to be responsible for more than one-third of BSIs in this series. This may reflect the presence of common risk factors for candidemia in nonneutropenic critically ill patients, which include the presence of intravascular devices, recent surgery, and broad-spectrum antibiotic therapy. 20 It is well reported that broad-spectrum antibiotics facilitate candidemia, and this microbiology pattern may have been influenced by antibiotic therapy policies at our institution. At our center, unlike other centers, patients did not receive routine antibiotic prophylaxis treatment for ECMO procedures; however, it is likely that many patients received antibiotics for their underlying illness or sepsis syndrome. Although fungal infections have been reported previously, most descriptions have involved urinary tract infections rather than BSIs. 12 In contrast to previous reports, we found coagulase-negative staphylococci responsible for only 1 BSI. 9, 11, 19 
Risk Factors
Considering infections at all sites, the only significant risk factor was the duration of ECMO support. This association has consistently been reported. [9] [10] [11] [12] [13] [14] [15] [16] 21, 22 Regarding BSI, not only the duration of support but also the illness severity before ECMO initiation and the number of RBC units transfused were significant risk factors. Additional work is required to elucidate the mechanism and causal relationship between these factors, but earlier reports have consistently noted an association between transfusion and mortality among critically ill patients. 23, 24 The independent relationship between patient severity before ECMO initiation and BSI occurrence is controversial in the literature, possibly because of the differences between studies, including differences in time periods 9,15 and methods used for assessment of severity (eg, SOFA score vs APACHE II score), differences in population characteristics, and differences in infection-definition criteria. 9, 14, 15 Interestingly, central VA ECMO, in which an open chest wound is present, was not associated with a higher infection rate in our study, in contrast to previous reports. 10, 11, 19, 22 Moreover, some authors have shown that the VV mode and immunosuppression were associated with nosocomial infection; however, we did not observe this association.
14
Impact on Prognosis
Patients with and patients without a nosocomial infection while receiving ECMO had similar mortality rates; however, infection was associated with longer ICU and hospital stays. It is interesting to note that we cannot conclude whether infections caused prolonged ECMO or prolonged ECMO caused infections. These findings are consistent with previous reports. 9, 14, 15, 22 Nonetheless, some studies, particularly those focused on pediatric patients, have reported that nosocomial infection or sepsis had a significant impact on mortality. 16, 21, 25 Bizzaro et al 19 also mentioned an association between infection and mortality in pediatric patients but not in adults.
Limitations and Conclusions
This study has several limitations. First, this was a singlecenter retrospective study. Second, the NHSN definitions, although regarded as an international standard for epidemiological studies, are of uncertain sensitivity and specificity in this patient population and necessitated adaptations. Third, because medical details were only available from our center, we did not consider infection that was present before retrieval. However, most retrieved patients with ECMO were transferred within a 24-hour period, and infections that occurred after less than 48 hours of ECMO were, by definition, not considered. Fourth, no extensive information was available about the presence and the characteristic (timing, duration, and type) of antimicrobial agents, so their effect on the findings of this study is unknown. Finally, we did not record the requirement for an intra-aortic balloon pump, which may have been a supplementary portal of entry for microorganisms and a risk factor for infection.
In conclusion, we have confirmed that nosocomial infections are common in patients who receive ECMO. We observed a high incidence of candidemia among blood cultures and observed a high overall incidence of Enterobacteriaceae. A future strategy of routine antifungal prophylaxis for patients who receive prolonged ECMO deserves consideration and prospective study. Potential conflicts of interest. All authors report no conflicts of interest relevant to this article. All authors submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest, and the conflicts that the editors consider relevant to this article are disclosed here.
